Compare NBIX & BSAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | BSAC |
|---|---|---|
| Founded | 1992 | 1977 |
| Country | United States | Chile |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 14.3B |
| IPO Year | 1996 | 2002 |
| Metric | NBIX | BSAC |
|---|---|---|
| Price | $174.19 | $33.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 3 |
| Target Price | ★ $180.91 | $33.00 |
| AVG Volume (30 Days) | ★ 1.1M | 365.5K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.51% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | $37.15 |
| Revenue Next Year | $13.14 | $7.52 |
| P/E Ratio | $91.24 | ★ $14.40 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $22.77 |
| 52 Week High | $174.38 | $37.72 |
| Indicator | NBIX | BSAC |
|---|---|---|
| Relative Strength Index (RSI) | 67.99 | 57.38 |
| Support Level | $153.96 | $31.65 |
| Resistance Level | N/A | $33.12 |
| Average True Range (ATR) | 4.48 | 0.82 |
| MACD | 0.66 | 0.06 |
| Stochastic Oscillator | 95.56 | 59.63 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.